Tezepelumab - Amgen/AstraZeneca

Drug Profile

Tezepelumab - Amgen/AstraZeneca

Alternative Names: AMG 157; MEDI-9929

Latest Information Update: 10 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen
  • Developer Amgen; AstraZeneca; Bispebjerg Hospital; Lund University; MedImmune; University of Copenhagen; University of Newcastle, Australia
  • Class Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Thymic stromal lymphopoietin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Asthma
  • Phase II Atopic dermatitis

Most Recent Events

  • 06 Sep 2018 Tezepelumab - Amgen/AstraZeneca receives Breakthrough Therapy status for Asthma in USA
  • 24 Jun 2018 Biomarkers information updated
  • 02 Mar 2018 Interim efficacy data from the phase IIb PATHWAY trial in Asthma presented at the 2018 Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-WAO-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top